Lpath gets FDA nod to initiate Phase I lpathomab clinical trial
The company intends to start the trial upon investigational review board approvals and expects the first subject to be dosed within two months. LPA is a bioactive lipid
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
The drug is approved for patients with HAP and VAP known or suspected to be caused by susceptible isolates of Staphylococcus aureus including methicillin-susceptible and methicillin-resistant S. aureus
The study, approved by the Food and Drug Administration (FDA), was conducted at Northwestern Memorial Hospital. The therapeutic approach utilizing a patient’s own cells expanded in the laboratory